The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Delta-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Delta-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is evidence to suggest a positive association between cannabis use and development of psychosis, in people susceptible to psychotic disorders.117–119”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [119]
In the citing paper
“Randomised controlled trials in laboratory conditions provide evidence that delta-9-tetrahydrocannabinol (THC), the main active compound in cannabis, can induce transient psychotic-like experiences (1).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
In the citing paper
“However, these experiences resolve within a few hours and rarely cause distress, in contrast to psychotic disorder where experiences are prolonged and impairment often substantial.”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
In the citing paper
“The experimental evidence showing that psychotic experiences occur during cannabis intoxication (1) indicates that cannabis has biological effects that could translate to chronic psychotic disorders.”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [1]
Citations
Cites
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · cited 1×
“D-9-THC The psychotropic effects of D-9-THC are mediated by partial agonist effects at CB-1 receptors (CB-1R) where it has modest affinity (Ki¼ 35–80 nmol) and low intrinsic activity (Compton et al, 1992; Gerard et al, 1991; Howlett et al, 2002; Matsuda et al, 1990).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationInternational Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · cited 1×
“…anterior cingulate cortex, and cerebellum (Egertova and Elphick, 2000; Egertova et al, 1998; Elphick and Egertova, 2001; Glass et al, 1997; Herkenham et al, 1991, 1990), brain regions that are relevant to both the known effects of cannabinoids and also regions that have been implicated in…”
BackgroundHerkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 1×
“…anterior cingulate cortex, and cerebellum (Egertova and Elphick, 2000; Egertova et al, 1998; Elphick and Egertova, 2001; Glass et al, 1997; Herkenham et al, 1991, 1990), brain regions that are relevant to both the known effects of cannabinoids and also regions that have been implicated in…”
BackgroundRole of Endogenous Cannabinoids in Synaptic Signaling
FREUND, T. F., KATONA, I., & PIOMELLI, D. (2003) · Physiological Reviews · doi:10.1152/physrev.00004.2003 · Cited by 1,574
Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.
Arseneault, L., Cannon, M., Poulton, R., Murray, R., Caspi, A., & Moffitt, T. E. (2002) · BMJ · doi:10.1136/bmj.325.7374.1212 · Cited by 1,399 · cited 1×
“…literature from pharmacological (Jones, 1971; Leweke et al, 2000, 1999b; McGuire et al, 1995), epidemiological (Andreasson et al, 1987, 1988, 1989; Arseneault et al, 2002; McGuire et al, 1995; Zammit et al, 2002), genetic (Ujike et al, 2002), neurochemical (Leweke et al, 1999a), and postmortem…”
BackgroundBorkowski, J. G., Benton, A. L., & Spreen, O. (1967) · Neuropsychologia · doi:10.1016/0028-3932(67)90015-2 · Cited by 1,302
Endocannabinoid Signaling in the Brain
Wilson, R. I., & Nicoll, R. A. (2002) · Science · doi:10.1126/science.1063545 · Cited by 1,260
Katona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218
Research works printed but not linked: 6
- Belger A, Puce A, Krystal JH, Gore JC, Goldman-Rakic P, McCarthy G (1998). Dissociation of mnemonic perceptual processes during spatial nonspatial working memory using fMRI. Hum Brain Mapping 6: 14–32. · DOI · Paper page
- Gold MS (1991). Marijuana In: Miller eNS (ed). Comprehensive Handbook of Alcohol Drug Addiction. Marcel Decker: New York. pp 353–376.
- Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K et al (1999b). Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19: 4544–4558. · DOI · Paper page
- Moreau J (1973) In: Peters NGH (ed). Hashish Mental Illness. Raven Press: New York. pp 245.
- Moreau de Tours J (1973). Sobre el hachisch y la alienacion mental. Actas Luso-Espanolas Neurol Psiquiatr Cienc Afines 1: 477–484.
- Wall ME, Brine DR, Perez-Reyes M (1976). Metabolism of cannabinoids in man In: Braude MC, Szara S (eds). Pharmacology of Marihuana Vol 1, pp 536.
Cited by
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
van Os, J., & Kapur, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60995-8 · Cited by 1,971
Chronic stress, drug use, and vulnerability to addiction
Sinha, R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1441.030 · Cited by 1,904
The environment and schizophrenia
van Os, J., Kenis, G., & Rutten, B. P. F. (2010) · Nature · doi:10.1038/nature09563 · Cited by 1,572
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
An Introduction to the Endogenous Cannabinoid System
Lu, H.-C., & Mackie, K. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.07.028 · Cited by 1,234
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.3278 · Cited by 867
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Suspicious minds: The psychology of persecutory delusions
Freeman, D. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2006.10.004 · Cited by 814
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680
Acute and Chronic Effects of Cannabinoids on Human Cognition—A Systematic Review
Broyd, S. J., van Hell, H. H., Beale, C., Yücel, M., & Solowij, N. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.12.002 · Cited by 674
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617
Self-citationDi Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., et al. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00117-5 · Cited by 588
High-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Cannabis, a complex plant: different compounds and different effects on individuals
Atakan, Z. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312457586 · Cited by 544
The acute effects of cannabinoids on memory in humans: a review
Ranganathan, M., & D’Souza, D. C. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0508-y · Cited by 525
Self-citationCannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509
Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning
Lesh, T. A., Niendam, T. A., Minzenberg, M. J., & Carter, C. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.156 · Cited by 506
Review of the Endocannabinoid System
Lu, H.-C., & Mackie, K. (2021) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 491
van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn101 · Cited by 489
Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt181 · Cited by 470
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
Englund, A., Morrison, P. D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., Stone, J. M., Reichenberg, A., Brenneisen, R., Holt, D., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112460109 · Cited by 462
The Environment and Schizophrenia: The Role of Cannabis Use
Henquet, C. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi027 · Cited by 454
Young adult sequelae of adolescent cannabis use: an integrative analysis.
Silins, E., Horwood, L. J., Patton, G. C., Fergusson, D. M., Olsson, C. A., Hutchinson, D. M., Spry, E., Toumbourou, J. W., Degenhardt, L., Swift, W., et al. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70307-4 · Cited by 443
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control
Ramaekers, J. G., Kauert, G., van Ruitenbeek, P., Theunissen, E. L., Schneider, E., & Moeller, M. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301068 · Cited by 397
From drugs to deprivation: A Bayesian framework for understanding models of psychosis
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1561-0 · Cited by 367
“…top-down influences would suggest that hallucinations should not pre-dominate under Δ9-THC administration, and this appears to be the case, however, that delusion-like ideas would be predicted, and this is borne out by studies exploring the impact of THC on healthy volunteers (D'Souza et al. 2004).”
BackgroundResultΔ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum
Bossong, M. G., van Berckel, B. N., Boellaard, R., Zuurman, L., Schuit, R. C., Windhorst, A. D., van Gerven, J. M. A., Ramsey, N. F., Lammertsma, A. A., & Kahn, R. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.138 · Cited by 392
Keep off the grass? Cannabis, cognition and addiction
Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 389
The Chronic Effects of Cannabis on Memory in Humans: A Review
Solowij, N., & Battisti, R. (2008) · Current Drug Abuse Reviewse · doi:10.2174/1874473710801010081 · Cited by 380
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360
Schizophrenia: a tale of two critical periods for prefrontal cortical development
Selemon, L. D., & Zecevic, N. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.115 · Cited by 336
Stress-related factors in cannabis use and misuse: Implications for prevention and treatment
Hyman, S. M., & Sinha, R. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.08.005 · Cited by 344
“…cannabis intake activates the CRF-HPA axis both following acute administration of cannabinoid receptor agonists and THC in animals and in humans (D’Souza et al., 2004; Kumar and Chen, 1983; Puder et al., 1982; Martin-Calderon et al., 1998) as well as during withdrawal (de Fonseca, Carrera,…”
BackgroundFreeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Modelling suicide and unemployment: a longitudinal analysis covering 63 countries, 2000–11
Nordt, C., Warnke, I., Seifritz, E., & Kawohl, W. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00118-7 · Cited by 322
Cannabis, the mind and society: the hash realities
Murray, R. M., Morrison, P. D., Henquet, C., & Forti, M. D. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2253 · Cited by 322
Gone to Pot – A Review of the Association between Cannabis and Psychosis
Radhakrishnan, R., Wilkinson, S. T., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00054 · Cited by 310
Self-citationFreeman, T. P., & Winstock, A. R. (2015) · Psychological Medicine · doi:10.1017/s0033291715001178 · Cited by 308
Morgan, C. J. A., Schafer, G., Freeman, T. P., & Curran, H. V. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.077503 · Cited by 305
Smart, R., & Pacula, R. L. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1669626 · Cited by 305
“effects and psycho-motor impairments (66,67), brain development and functioning (68), use disorders (69), and psychosis (70,71).”
BackgroundReviewing the ketamine model for schizophrenia
Frohlich, J., & Van Horn, J. D. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881113512909 · Cited by 303
Acute and chronic effects of ketamine upon human memory: a review
Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 302
Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Morgan, C. J. A., & Curran, H. V. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046649 · Cited by 300
Synthetic cannabinoid JWH-018 and psychosis: An explorative study
Every-Palmer, S. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.01.012 · Cited by 299
Morrison, P. D., Zois, V., McKeown, D. A., Lee, T. D., Holt, D. W., Powell, J. F., Kapur, S., & Murray, R. M. (2009) · Psychological Medicine · doi:10.1017/s0033291709005522 · Cited by 298
Cannabis and psychosis/schizophrenia: human studies
D’Souza, D. C., Sewell, R. A., & Ranganathan, M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0024-2 · Cited by 295
Self-citationMartin-Santos, R., A. Crippa, J., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M., Langohr, K., Farre, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 295
Ramaekers, J. G., Moeller, M. R., van Ruitenbeek, P., Theunissen, E. L., Schneider, E., & Kauert, G. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.015 · Cited by 290
Mondelli, V., Dazzan, P., Hepgul, N., Di Forti, M., Aas, M., D'Albenzio, A., Di Nicola, M., Fisher, H., Handley, R., Marques, T. R., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.013 · Cited by 278
“…al., 2009; Nemeroff, 2004; Read et al., 2005); the distress and severity of the psychotic experience (Dinan, 2005); heavy tobacco smoking (De Leon andDiaz, 2005); andan increaseduse of cannabis (Di Forti et al., 2007), which in turn increases cortisol levels in humans (D'Souza et al., 2004, 2005).”
Effects of cannabis use on outcomes of psychotic disorders: systematic review
Zammit, S., Moore, T. H. M., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., & Lewis, G. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.046375 · Cited by 275
Moreira, F. A., Grieb, M., & Lutz, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.09.003 · Cited by 272
Eggan, S. M., & Lewis, D. A. (2006) · Cerebral Cortex · doi:10.1093/cercor/bhj136 · Cited by 264
A systematic review of the antipsychotic properties of cannabidiol in humans
Iseger, T. A., & Bossong, M. G. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.033 · Cited by 261
D'Souza, D. C., Ranganathan, M., Braley, G., Gueorguieva, R., Zimolo, Z., Cooper, T., Perry, E., & Krystal, J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301643 · Cited by 262
Self-citationEuropean Network of National Networks studying Gene-Environment Interactions in Schizophrenia (EU-GEI) (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu069 · Cited by 259
Positive and Negative Effects of Cannabis and Cannabinoids on Health
Cohen, K., Weizman, A., & Weinstein, A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1381 · Cited by 255
Cannabinoid Modulation of Amygdala Reactivity to Social Signals of Threat in Humans
Phan, K. L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., & de Wit, H. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5603-07.2008 · Cited by 251
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253
Cannabis and mental illness: a review
Lowe, D. J. E., Sasiadek, J. D., Coles, A. S., & George, T. P. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0970-7 · Cited by 253
Melis, M., Perra, S., Muntoni, A. L., Pillolla, G., Lutz, B., Marsicano, G., Di Marzo, V., Gessa, G. L., & Pistis, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3502-04.2004 · Cited by 253
Reasons for increased substance use in psychosis
Gregg, L., Barrowclough, C., & Haddock, G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2006.09.004 · Cited by 249
The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
van Amsterdam, J., Brunt, T., & van den Brink, W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565142 · Cited by 244
Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models
Malone, D. T., Hill, M. N., & Rubino, T. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00721.x · Cited by 237
Glutamatergic model psychoses: prediction error, learning, and inference
Corlett, P. R., Honey, G. D., Krystal, J. H., & Fletcher, P. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.163 · Cited by 229
Self-citationFrom prediction error to psychosis: Ketamine as a pharmacological model of delusions
Corlett, P. R., Honey, G. D., & Fletcher, P. C. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077716 · Cited by 227
Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213
“Concerning the effects of cannabis in humans, independent of the disorder, many of the herbal cannabis or D9-THC actions are biphasic and bidirectional, depending on the mode of administration, dose, personality, time frame, degree of tolerance, and various other environmental and individual factors.”
BackgroundInfluentialAssociation of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence
Hines, L. A., Freeman, T. P., Gage, S. H., Zammit, S., Hickman, M., Cannon, M., Munafo, M., MacLeod, J., & Heron, J. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.1035 · Cited by 208
Bhattacharyya, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.161 · Cited by 203
Genetic predisposition to schizophrenia associated with increased use of cannabis
Power, R. A., Verweij, K. J. H., Zuhair, M., Montgomery, G. W., Henders, A. K., Heath, A. C., Madden, P. A. F., Medland, S. E., Wray, N. R., & Martin, N. G. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.51 · Cited by 196
Morgan, C. J., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.58 · Cited by 196
Morgan, C. J. A., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001322 · Cited by 195
Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition
Borgwardt, S. J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.011 · Cited by 195
Cass, D. K., Flores-Barrera, E., Thomases, D. R., Vital, W. F., Caballero, A., & Tseng, K. Y. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.14 · Cited by 181
Kinsey, S. G., O'Neal, S. T., Long, J. Z., Cravatt, B. F., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.002 · Cited by 170
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163
“For instance, the subjective effects of THC tend to be biphasic; low doses generally promote anxiolytic-like effects, whereas higher doses may induce anxiogenic-like effects (D’Souza et al., 2004; Genn et al., 2004; Viveros et al., 2005).”
Pariante, C. M., Dazzan, P., Danese, A., Morgan, K. D., Brudaglio, F., Morgan, C., Fearon, P., Orr, K., Hutchinson, G., Pantelis, C., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300766 · Cited by 152
“Furthermore, cannabis abuse has been identified as a risk factor for schizophrenia (Arseneault et al, 2004), and activation of the hormonal stress response by cannabis could also participate to this phenomenon (D’Souza et al, 2004; D’Souza et al, 2005).”
BackgroundWinton-Brown, T. T., Allen, P., Bhattacharrya, S., Borgwardt, S. J., Fusar-Poli, P., Crippa, J. A., Seal, M. L., Martin-Santos, R., Ffytche, D., Zuardi, A. W., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.17 · Cited by 146
Drug-induced stress responses and addiction risk and relapse
Wemm, S. E., & Sinha, R. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100148 · Cited by 144
Prediction error, ketamine and psychosis: An updated model
Corlett, P. R., Honey, G. D., & Fletcher, P. C. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116650087 · Cited by 142
“Cannabinoids such as Δ-9-THC also have psychotomimetic effects (D’Souza et al., 2004).”
BackgroundMason, O. J., Morgan, C. J. M., Stefanovic, A., & Curran, H. V. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.02.020 · Cited by 135
Passie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1377 · Cited by 117
Effects of increasing cannabis potency on adolescent health
Wilson, J., Freeman, T. P., & Mackie, C. J. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30342-0 · Cited by 113
Aragona, M., Onesti, E., Tomassini, V., Conte, A., Gupta, S., Gilio, F., Pantano, P., Pozzilli, C., & Inghilleri, M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181633497 · Cited by 109
“The acute administration of cannabis was reported to produce transient effects on several neuropsychological functions (eg, attention, memory, visual-motor coordination, verbal fluency, and psychomotor speed).(3,9,10) In Bheavy users[ (eg, subjects smoking several joints per day, during periods of many years), a long-…”
BackgroundResultEffects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.
Trigo, J. M., Lagzdins, D., Rehm, J., Selby, P., Gamaleddin, I., Fischer, B., Barnes, A. J., Huestis, M. A., & Le Foll, B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.020 · Cited by 97
“THC produces psychotic-like and anxiogenic effects in humans under some conditions (D’Souza et al., 2005, 2004, 2008).”
BackgroundEndocannabinoid signaling and the hypothalamic-Pituitary-Adrenal axis
Hillard, C. J., Beatka, M., & Sarvaideo, J. (2016) · Comprehensive physiology · doi:10.1002/cphy.c160005 · Cited by 93
Koethe, D., Gerth, C. W., Neatby, M. A., Haensel, A., Thies, M., Schneider, U., Emrich, H. M., Klosterkötter, J., Schultze-Lutter, F., & Leweke, F. M. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.023 · Cited by 93
“In linewith the findings of D'Souza et al. (2004), we have no evidence at all for a subsequent development of cannabis abuse or dependence or any psychotic disorder in our volunteers exposed to Δ-THC.”
BackgroundResultInfluentialGage, S. H., Hickman, M., Heron, J., Munafò, M. R., Lewis, G., Macleod, J., & Zammit, S. (2014) · Psychological Medicine · doi:10.1017/s0033291714000531 · Cited by 91
An Internet survey of marijuana and hot shower use in adults with cyclic vomiting syndrome (CVS)
Venkatesan, T., Sengupta, J., Lodhi, A., Schroeder, A., Adams, K., Hogan, W. J., Wang, Y., Andrews, C., & Storr, M. (2014) · Experimental Brain Research · doi:10.1007/s00221-014-3967-0 · Cited by 86
Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.002 · Cited by 83
Self-citation
Metadata
- Authors
- D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H.
- Affiliations
- Yale University (US)
- Nathan Kline Institute for Psychiatric Research (US)
- Venue
- Neuropsychopharmacology
- Published
- 2004-06-02
- Volume
- 29
- Issue
- 8
- Pages
- 1558-1572
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1996278273
- Cited by
- 1,024
- References
- 143
- Citations by year
- 2026: 28 · 2025: 24 · 2024: 40 · 2023: 45 · 2022: 66 · 2021: 64 · 2020: 91 · 2019: 50 · 2018: 57 · 2017: 61 · 2016: 58 · 2015: 49 · 2014: 55 · 2013: 36 · 2012: 55
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5k02aa000261-04)
- National Center for PTSD, U.S. Department of Veterans Affairs
- National Institute on Alcohol Abuse and Alcoholism (K02 AA00261-04)
- National Institute of Mental Health (R01 MH61019-02, MH 44866, MH61019-02, R01MH061019, P50 MH44866-15, P50MH044866)
- National Institute on Drug Abuse (R01DA012382, 1 DA12382-01)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- delta-9-tetrahydrocannabinol, psychotomimetic effects, psychosis, schizophrenia-like symptoms, positive and negative symptoms, cognitive impairment, working memory, distractibility, verbal fluency, plasma cortisol, anxiety, euphoria, altered perception, cannabinoid receptors, cannabis use, healthy volunteers, drug safety
- MeSH terms
- Adult, Anxiety, Arousal, Attention, Behavior, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Female, Hallucinogens, Hemodynamics, Humans, Hydrocortisone, Injections, Intravenous, Male, Memory, Short-Term, Panic, Prolactin, Psychiatric Status Rating Scales, Psychometrics, Psychoses, Substance-Induced, Mental Recall, Speech, Dronabinol, Verbal Learning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.